Liver Cancer Drugs Market 2024-2028: Size and Only curative option is surgical resection and transplantation; growth driven by the Type, Some of key Companies Positioned Strategically

The liver cancer drugs market size by Type (Immunotherapy and Targeted therapy) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 3287 million. The market is expected to grow at a CAGR of   10.03% between 2024 and 2028.

• In the liver cancer market, the selection of treatment options is contingent upon the disease's stage and the patient's liver function. Regrettably, disease-modifying drugs, capable of curing liver cancer, remain absent from both the market and the pipeline. Consequently, surgical resection and transplantation serve as the only potentially curative modalities. However, global consensus on surgical treatment as the recommended option for liver cancer is yet to be achieved due to disparities in healthcare systems among regions. Surgical candidates must meet stringent prerequisites, yet recurrence rates remain high.
• The liver cancer drugs market represents a significant business opportunity due to the rising prevalence of this malignancy and the increasing demand for effective treatments. Key players in this sector are investing heavily in research and development to bring innovative therapies to market. These include targeted therapies, immunotherapies, and chemotherapies. Market growth is driven by factors such as an aging population, increasing incidence of risk factors, and improving healthcare infrastructure. Despite challenges, the future looks promising for the liver cancer drugs market.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• Alnylam Pharmaceuticals Inc.
• AstraZeneca Plc
• Bayer AG
• Bristol Myers Squibb Co.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Eureka Therapeutics
• Exelixis Inc.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Lion TCR Pte. Ltd
• Merck and Co. Inc.
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Q BioMed Inc.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/